Startup entity
The clearest coverage concentration is regulation: 3 of 5 stories, with the rest divided among 2 other categories. FDA is most often covered alongside Biotech Startups, which appears in 2 of these 5 stories. The 146-day window averages about 0.2 stories each week.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 60 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is regulation: 3 of 5 stories, with the rest divided among 2 other categories. FDA is most often covered alongside Biotech Startups, which appears in 2 of these 5 stories. The 146-day window averages about 0.2 stories each week. Negative sentiment reaches 20% here, compared with 21% across the 1446-story beat baseline for the same window. The 7 average consequence score is above the beat benchmark of 6.7 in the same window. They are less corroborated than the beat average, carrying 2.6 original sources each against 2.8 for the same window. This profile follows 5 Startup stories mentioning FDA across the period from February 19, 2026 to July 14, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 1446 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FDA. Shared-story counts are live from our verified record — not editorial picks.
Market Outperformance
Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains.
TD Cowen Upgrade
Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
The biotech venture market is splitting in two: established clinical-stage companies are raising megafunds at a blistering pace, while preclinical and seed-stage biotechs face a deepening funding winter. The contrast underscores a structural shift in startup financing strategies.
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
The U.S. Food and Drug Administration is introducing a performance-based bonus system to reward staffers who complete drug reviews ahead of schedule. This regulatory shift aims to clear backlogs and could significantly shorten the path to market for biotech startups and their venture backers.
The FDA has proposed a groundbreaking regulatory system designed to streamline the approval of customized, 'N-of-1' therapies for ultra-rare diseases. This shift marks a transition from traditional mass-market drug evaluation to a platform-based approach, potentially unlocking significant venture investment in precision medicine.
Amai Proteins has received FDA GRAS approval for its designer protein sweetener, Sweelin, marking a pivotal regulatory milestone for the precision fermentation industry. This clearance allows the Israeli food-tech startup to begin large-scale commercialization in the U.S. food and beverage market.
FDA is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
